Figure 5.

Effect of nab-paclitaxel and bevacizumab on lymphatic and systemic metastases. Mice were treated with either two (A) or three (B) cycles of nab-paclitaxel alone, bevacizumab, or combination. Tumor-proximate LNs (n = 10) and lungs were harvested from mice in experimental groups when the mean tumor volume in the saline-treated group reached 2 cm³. After three cycles of chemotherapy, luciferase activity was determined in proximal and contralateral LNs, the lungs, and the brain. The results are presented as the mean light units x 10⁴ per group ± SE normalized per milligram of total protein. x-axis: Bevacizumab and ABX denote bevacizumab and nabpaclitaxel, respectively. Numbers above and below the solid line separating ABX and bevacizumab indicate the drugs and a dose expressed in milligrams per kilogram used for the treatment of each of the experimental groups.